- Visibility 134 Views
- Downloads 110 Downloads
- Permissions
- DOI 10.18231/j.sajcrr.v.12.i.3.2
-
CrossMark
Beyond sicca: A rare case of neuro- sjogren’s presenting as recurrent cerebral infarctions and syringomyelia
- Author Details:
-
Soumia M *
-
Sunita Aggarwal
-
Pradeep Kumar
-
Ravindra Kumar Saran
-
Rahul Yadav
-
Dheeraj Sharma
-
Anandswarup Chaudhari
Soumia M *
Background: Neurological involvement in primary Sjögren’s syndrome (pSS) is rare but can include serious central nervous system (CNS) manifestations such as recurrent strokes and myelopathy.
Case Presentation: A 27-year-old woman presented with progressive quadriparesis and dysarthria. Six months earlier, she had recovered from a similar episode of limb weakness. Neurological examination revealed spastic quadriparesis and right 12th cranial nerve palsy. Brain MRI showed chronic infarcts in the bilateral fronto-parietal cortex, right occipital lobe, and basal ganglia, with spinal MRI revealing diffuse cord thinning and a holocord syrinx. Carotid artery Doppler was normal. Autoimmune workup revealed ANA (1:320, speckled) and anti-Ro/SSA positivity. Labial gland biopsy confirmed pSS. CNS vasculitis secondary to pSS was diagnosed, and treatment included IV methylprednisolone followed by weekly rituximab.
Conclusion: This case underscores a rare but severe neurological manifestation of pSS with recurrent infarctions and myelopathy, highlighting the importance of early recognition and immunosuppressive treatment in young patients with unexplained CNS disease
References
- Konak HE, Gök K, Armağan B, Güven SC, Atalar E, Apaydın H, et al. Neurological involvement in patients with primary Sjögren’s syndrome: a retrospective cross-sectional study. Ann Indian Acad Neurol. 2023;26(4):424–30.
- Jagtap SV, Aramani SS, Mane A, Bonde V. Sialosis: Cytomorphological significance in the diagnosis of an uncommon entity. J Cytol. 2017;34(1):51–2.
- Perzyńska-Mazan J, Maślińska M, Gasik R. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018;56(2):99–105.
- Alexander EL, Ranzenbach MR, Kumar AJ. Anti-Ro (SS-A) autoantibodies in central nervous system disease associated with Sjögren’s syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology. 1994;44:899–908.
- Alexander EL. Neurologic disease in Sjögren’s syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle—a clinical review and update of immunopathogenesis. Rheum Dis Clin North Am. 1993;19(4):869–908.
- Shiboski CH, Shiboski SC, Seror R. American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data‐driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35–45.
- Mekinian A, Ravaud P, Larroche C, Hachulla E, Gombert B, Blanchard-Delaunay C, et al. Rituximab in central nervous system manifestations of patients with primary Sjögren’s syndrome: results from the AIR registry. Clin Exp Rheumatol. 2012;30(2):208–12.
- Lv C, Zhu F, Chen C, Liu Y, Luo C, Zhou D. A rare case report of primary Sjögren’s syndrome with clinical characteristics similar to those of CLIPPERS. BMC Neurol. 2022;22(1):414.
- Afzali AM, Stewart JJ, Watson RS. CNS demyelinating events in primary Sjögren’s syndrome: a single-center case series on the clinical phenotype. Front Neurol. 2023;14:1128315.
- Jaskólska M, Rytlewska M, Dułak NA. Diversity of central nervous system manifestations in Sjögren’s disease: a case-based review. Rheumatol Int. 2025;45(2):35.
- Li X, Lu Z, Wang Y. Syringomyelia-like syndrome in neuromyelitis optica spectrum disorder complicated with Sjögren’s syndrome: a case report. BMC Neurol. 2018(1):168.
- Li JA, Zhang D, Liu D, Liu X, Zhang S. Recurrent cerebral infarctions in primary Sjögren syndrome: a case report and literature review. Front Neurol. 2018;9:865.
- Fan W, Par-Young J, Li K. Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndrome. Clin Rheumatol. 2023;42(2):443–51.